A group of Ob-Gyns recently analyzed clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian cancer.
With his new, five-year, $1.8 million award, Dr. Gong hopes to improve PARPi therapy by better understanding the mechanisms of resistance.
A retrospective review found that the presence of variants of uncertain significance on multigene panel testing does not increase the rate of contralateral prophylactic mastectomies.
The data are promising regarding PARP inhibitors, especially in recurrent ovarian cancer. Gynecologic oncologists are awaiting results of current trials in patients with newly diagnosed ovarian cancer as part of primary therapy.